MENU
+Compare
XBI
ETF ticker: NYSE ARCA
AS OF
Dec 18, 10:51 AM (EDT)
Price
$94.08
Change
-$0.51 (-0.54%)
Net Assets
6.52B

XBI stock forecast, quote, news & analysis

Category: @Health
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for XBI with price predictions
Dec 17, 2024

Momentum Indicator for XBI turns negative, indicating new downward trend

XBI saw its Momentum Indicator move below the 0 level on December 10, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In of the 94 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on December 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

XBI moved below its 50-day moving average on December 10, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XBI crossed bearishly below the 50-day moving average on December 12, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where XBI's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 236 cases where XBI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Biotech ETF ETF is 9.44B. The market cap for tickers in the group ranges from 122.17M to 322.43B. ABBV holds the highest valuation in this group at 322.43B. The lowest valued company is EDIT at 122.17M.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Biotech ETF ETF was 15%. For the same ETF, the average monthly price growth was 66%, and the average quarterly price growth was 417%. ARQT experienced the highest price growth at 13%, while KROS experienced the biggest fall at -73%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Biotech ETF ETF was 13%. For the same stocks of the ETF, the average monthly volume growth was -36% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 79
Price Growth Rating: 57
SMR Rating: 86
Profit Risk Rating: 77
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com